Insmed (INSM) EBT Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Insmed (INSM) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,328.00 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 29,565.00 |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -65,875.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29,565.00 |
| Mar 31, 2026 | 22,246.00 |
| Dec 31, 2025 | 10,041.00 |
| Sep 30, 2025 | -2,407.00 |
| Jun 30, 2025 | 3,350.00 |
| Mar 31, 2025 | -6,815.00 |
| Dec 31, 2024 | -320.00 |
| Sep 30, 2024 | -3,465.00 |
| Jun 30, 2024 | -1,552.00 |
| Mar 31, 2024 | 3,696.00 |
| Dec 31, 2023 | 4,869.00 |
| Sep 30, 2023 | -723.00 |
| Jun 30, 2023 | -17,043.00 |
| Mar 31, 2023 | -6,680.00 |
| Dec 31, 2022 | -6,844.00 |
| Sep 30, 2022 | 5,350.00 |
| Jun 30, 2022 | 11,136.00 |
| Mar 31, 2022 | 4,984.00 |
| Dec 31, 2021 | 4,393.00 |
| Sep 30, 2021 | -10,144.00 |